Vistagen Q2 FY2025 net loss $13.0M; Phase 3 SAD trials on track for 2025 data

Vistagen Therapeutics, Inc.

2025-Q2 EPS reported -$0.77 vs consensus -$0.48 ▼ miss (-59.5%)

Net loss of $13.0M for Q2 ended Sep 30, 2024 vs $6.6M a year ago, driven by higher R&D costs.
R&D expense $10.2M (up from $3.9M) due to fasedienol PALISADE Phase 3 program costs.
Cash, cash equivalents and marketable securities $97.6M as of Sep 30, 2024.
PALISADE-3 and PALISADE-4 Phase 3 trials for fasedienol in social anxiety disorder actively recruiting; top-line results expected in 2025.
Itruvone Phase 2B prep for MDD and PH80 IND-enabling program for menopausal hot flashes ongoing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.